BNP Paribas Asset Management
CYTK icon

BNP Paribas Asset Management’s Cytokinetics CYTK Stock Holding History

BNP Paribas Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.5M Buy
827,810
+113,466
+16% +$8.15M 0.07% 260
2026
Q1 		$47.1M Sell
714,344
-113,519
-14% -$7.21M 0.05% 328
2025
Q4 		$52.6M Buy
827,863
+42,863
+5% +$2.67M 0.06% 292
2025
Q3 		$43.1M Buy
785,000
+108,720
+16% +$4.48M 0.11% 201
2025
Q2 		$22.3M Buy
676,280
+153,812
+29% +$5.35M 0.05% 329
2025
Q1 		$21M Buy
522,468
+33,106
+7% +$1.52M 0.06% 331
2024
Q4 		$23M Buy
489,362
+161,290
+49% +$8.38M 0.06% 306
2024
Q3 		$17.3M Sell
328,072
-55,970
-15% -$3.12M 0.04% 333
2024
Q2 		$20.8M Buy
384,042
+29,544
+8% +$1.78M 0.05% 292
2024
Q1 		$24.9M Sell
354,498
-112,580
-24% -$8.71M 0.07% 275
2023
Q4 		$39M Sell
467,078
-149,400
-24% -$5.41M 0.11% 211
2023
Q3 		$18.2M Buy
616,478
+187,259
+44% +$6.24M 0.06% 306
2023
Q2 		$14M Sell
429,219
-135,533
-24% -$5.01M 0.04% 340
2023
Q1 		$19.9M Sell
564,752
-34,790
-6% -$1.42M 0.07% 293
2022
Q4 		$27.5M Sell
599,542
-29,257
-5% -$1.26M 0.1% 240
2022
Q3 		$30.5M Sell
628,799
-24,714
-4% -$1.19M 0.12% 199
2022
Q2 		$25.7M Sell
653,513
-139,643
-18% -$5.62M 0.1% 234
2022
Q1 		$29.2M Sell
793,156
-47,445
-6% -$1.69M 0.1% 239
2021
Q4 		$38.3M Buy
840,601
+18,854
+2% +$727K 0.13% 198
2021
Q3 		$29.4M Sell
821,747
-274,057
-25% -$8.07M 0.11% 223
2021
Q2 		$21.7M Buy
1,095,804
+189,082
+21% +$4.44M 0.08% 298
2021
Q1 		$21.1M Buy
906,722
+271,636
+43% +$5.8M 0.09% 270
2020
Q4 		$13.2M Buy
+635,086
New +$11.6M 0.06% 329

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's CYTK Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Cytokinetics (CYTK) stake by 16% in Q2 2026, buying an estimated $8.15M and bringing the position to 827,810 shares worth $70.5M. The position accounts for 0.07% of the portfolio, ranked #260.

BNP Paribas Asset Management first reported a position in CYTK in Q4 2020 and has held it in 23 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • BNP Paribas Asset Management held 827,810 shares of Cytokinetics worth $70.5M as of Q2 2026.
  • BNP Paribas Asset Management bought 113,466 Cytokinetics shares in Q2 2026, an estimated $8.15M.
  • Cytokinetics made up 0.07% of BNP Paribas Asset Management's portfolio in Q2 2026, its #260 holding.
  • BNP Paribas Asset Management first reported a position in Cytokinetics in Q4 2020 and has held it in 23 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.